Blueprint Medicines Corp Company Profile (NASDAQ:BPMC)

About Blueprint Medicines Corp (NASDAQ:BPMC)

Blueprint Medicines Corp logoBlueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $1.21 billion
  • Outstanding Shares: 33,249,000
Average Prices:
  • 50 Day Moving Avg: $42.86
  • 200 Day Moving Avg: $36.37
  • 52 Week Range: $17.35 - $48.85
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.95
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $26.76 million
  • Price / Sales: 45.26
  • Book Value: $5.66 per share
  • Price / Book: 6.44
  • EBIDTA: ($83,890,000.00)
  • Net Margins: -270.30%
  • Return on Equity: -55.22%
  • Return on Assets: -36.15%
  • Debt-to-Equity Ratio: 0.05%
  • Current Ratio: 6.54%
  • Quick Ratio: 6.54%
  • Average Volume: 476,888 shs.
  • Beta: 1.44
  • Short Ratio: 7

Frequently Asked Questions for Blueprint Medicines Corp (NASDAQ:BPMC)

What is Blueprint Medicines Corp's stock symbol?

Blueprint Medicines Corp trades on the NASDAQ under the ticker symbol "BPMC."

How were Blueprint Medicines Corp's earnings last quarter?

Blueprint Medicines Corp (NASDAQ:BPMC) announced its quarterly earnings results on Wednesday, May, 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.73) by $0.11. The firm had revenue of $5.84 million for the quarter, compared to analyst estimates of $6.02 million. Blueprint Medicines Corp had a negative net margin of 270.30% and a negative return on equity of 55.22%. The firm's quarterly revenue was down 14.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.57) earnings per share. View Blueprint Medicines Corp's Earnings History.

Where is Blueprint Medicines Corp's stock going? Where will Blueprint Medicines Corp's stock price be in 2017?

7 analysts have issued twelve-month price targets for Blueprint Medicines Corp's stock. Their predictions range from $33.19 to $52.00. On average, they anticipate Blueprint Medicines Corp's share price to reach $45.74 in the next year. View Analyst Ratings for Blueprint Medicines Corp.

What are analysts saying about Blueprint Medicines Corp stock?

Here are some recent quotes from research analysts about Blueprint Medicines Corp stock:

  • 1. According to Zacks Investment Research, "Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA. " (4/18/2017)
  • 2. Jefferies Group LLC analysts commented, "Utilizing its drug discovery platform, BPMC is well positioned to build a balanced pipeline of proprietary & partnered products for cancer/rare disease. Early Ph1 data suggests its two candidates (BLU-285 & BLU-554) are effective & differentiated from current limited tx options, supporting further development." (12/14/2016)
  • 3. Cowen and Company analysts commented, "“We are encouraged by the early efficacy seen following BLU-285 administration. BLU-285 has clear activity as evidenced by the observed reductions in serum tryptase and mast cell burden. Safety and tolerability were also good, and provide much room for further dose escalation. We note that BLU-285 has been shown to be safe and well tolerated at doses up to 400mg in GIST, and that dose escalation and longer-term follow up in SM will likely be associated with even more substantial benefit. While it remains to be seen how BLU-285’s profile might stack up relative to other kinase inhibitors including NVS’s midostaurin (pending FDA approval for SM), we expect that more selective and potent inhibition of c-KIT will translate into clinical advantages. We believe advanced SM could represent a >$500MM WW opportunity for BLU-285.”" (12/5/2016)

Who are some of Blueprint Medicines Corp's key competitors?

Who are Blueprint Medicines Corp's key executives?

Blueprint Medicines Corp's management team includes the folowing people:

  • Daniel S. Lynch, Chairman of the Board
  • Jeffrey W Albers, President, Chief Executive Officer, Director
  • Michael Landsittel, Principal Financial Officer, Principal Accounting Officer, Senior Director of Finance
  • Tracey Lorene Mccain, Executive Vice President, Chief Legal Officer, Secretary
  • Christoph Lengauer Ph.D., Executive Vice President
  • Marion Dorsch Ph.D., Chief Scientific Officer
  • Anthony L. Boral M.D. Ph.D., Chief Medical Officer
  • Kathryn Haviland, Chief Business Officer
  • Alexis Borisy, Director
  • Mark Alan Goldberg M.D., Director

When did Blueprint Medicines Corp IPO?

(BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who owns Blueprint Medicines Corp stock?

Blueprint Medicines Corp's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.39%), Wellington Management Group LLP (11.49%), BIOTECHNOLOGY VALUE FUND L P (4.90%), Vanguard Group Inc. (3.67%), Alliancebernstein L.P. (2.93%) and Driehaus Capital Management LLC (2.68%). Company insiders that own Blueprint Medicines Corp stock include Christoph Lengauer, Daniel Lynch, Fmr Llc, Jeffrey W Albers, Kevin P Starr, Mark J Levin and Rock Ventures Ii LP Third. View Institutional Ownership Trends for Blueprint Medicines Corp.

Who sold Blueprint Medicines Corp stock? Who is selling Blueprint Medicines Corp stock?

Blueprint Medicines Corp's stock was sold by a variety of institutional investors in the last quarter, including Sandia Holdings LLC, Driehaus Capital Management LLC, FIL Ltd, Foresite Capital Management III LLC, Pictet Asset Management Ltd., JPMorgan Chase & Co., Laurion Capital Management LP and SG Americas Securities LLC. Company insiders that have sold Blueprint Medicines Corp stock in the last year include Daniel Lynch, Jeffrey W Albers, Kevin P Starr, Mark J Levin and Rock Ventures Ii LP Third. View Insider Buying and Selling for Blueprint Medicines Corp.

Who bought Blueprint Medicines Corp stock? Who is buying Blueprint Medicines Corp stock?

Blueprint Medicines Corp's stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Alliancebernstein L.P., FMR LLC, OppenheimerFunds Inc., Redmile Group LLC, Vanguard Group Inc., Goldman Sachs Group Inc. and Perceptive Advisors LLC. View Insider Buying and Selling for Blueprint Medicines Corp.

How do I buy Blueprint Medicines Corp stock?

Shares of Blueprint Medicines Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Blueprint Medicines Corp's stock price today?

One share of Blueprint Medicines Corp stock can currently be purchased for approximately $36.43.

MarketBeat Community Rating for Blueprint Medicines Corp (NASDAQ BPMC)
Community Ranking:  3.2 out of 5 (  )
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  159
MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Blueprint Medicines Corp (NASDAQ:BPMC) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $45.74 (25.56% upside)

Analysts' Ratings History for Blueprint Medicines Corp (NASDAQ:BPMC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/4/2017Jefferies Group LLCBoost Price TargetBuy$42.00 -> $52.00MediumView Rating Details
4/5/2017WedbushBoost Price TargetOutperform -> Outperform$43.00 -> $50.00LowView Rating Details
4/4/2017Canaccord GenuityBoost Price TargetBuy$40.00 -> $42.00LowView Rating Details
3/22/2017JMP SecuritiesInitiated CoverageOutperform$37.00 -> $46.00LowView Rating Details
3/13/2017Goldman Sachs Group IncUpgradeNeutral -> Buy$52.00HighView Rating Details
2/15/2017Morgan StanleyInitiated CoverageOverweight$45.00N/AView Rating Details
12/5/2016Cowen and CompanyReiterated RatingBuy$38.33 -> $33.19N/AView Rating Details
5/27/2016Raymond James Financial, Inc.Initiated CoverageOutperform$23.00N/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$54.00 -> $37.00N/AView Rating Details
(Data available from 5/30/2015 forward)


Earnings History for Blueprint Medicines Corp (NASDAQ:BPMC)
Earnings by Quarter for Blueprint Medicines Corp (NASDAQ:BPMC)
Earnings History by Quarter for Blueprint Medicines Corp (NASDAQ BPMC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017Q1 2017($0.73)($0.84)$6.02 million$5.84 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.76)($0.75)$6.31 million$7.69 millionViewListenView Earnings Details
11/10/2016Q316($0.77)($0.62)$6.06 million$6.16 millionViewListenView Earnings Details
8/9/2016Q216($0.73)($0.70)$4.41 million$7.07 millionViewListenView Earnings Details
5/10/2016Q116($0.70)($0.57)$3.24 million$6.90 millionViewListenView Earnings Details
3/11/2016Q415($0.53)($0.58)$2.85 million$4.64 millionViewN/AView Earnings Details
11/9/2015Q3($0.54)($0.47)$1.83 million$3.43 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Blueprint Medicines Corp (NASDAQ:BPMC)
2017 EPS Consensus Estimate: ($3.04)
2018 EPS Consensus Estimate: ($3.79)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.72)($0.72)($0.72)
Q2 20172($0.75)($0.75)($0.75)
Q3 20172($0.78)($0.77)($0.78)
Q4 20172($0.80)($0.79)($0.80)
Q1 20181($0.83)($0.83)($0.83)
Q2 20181($0.88)($0.88)($0.88)
Q3 20181($1.03)($1.03)($1.03)
Q4 20181($1.05)($1.05)($1.05)
(Data provided by Zacks Investment Research)


Dividend History for Blueprint Medicines Corp (NASDAQ:BPMC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Blueprint Medicines Corp (NASDAQ:BPMC)
Insider Ownership Percentage: 3.93%
Institutional Ownership Percentage: 59.51%
Insider Trades by Quarter for Blueprint Medicines Corp (NASDAQ:BPMC)
Institutional Ownership by Quarter for Blueprint Medicines Corp (NASDAQ:BPMC)
Insider Trades by Quarter for Blueprint Medicines Corp (NASDAQ:BPMC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/16/2017Mark J LevinMajor ShareholderSell30,000$40.88$1,226,400.00View SEC Filing  
2/7/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell1,000,000$35.28$35,280,000.00View SEC Filing  
12/19/2016Kevin P. StarrMajor ShareholderSell106,489$28.19$3,001,924.91View SEC Filing  
12/1/2016Daniel LynchDirectorSell200$30.02$6,004.00View SEC Filing  
10/13/2016Daniel LynchDirectorSell21,800$30.02$654,436.00View SEC Filing  
8/8/2016Jeffrey W AlbersCEOSell17,000$22.86$388,620.00View SEC Filing  
6/3/2016Jeffrey W AlbersCEOSell17,000$20.03$340,510.00View SEC Filing  
4/13/2016Christoph LengauerInsiderSell15,872$20.01$317,598.72View SEC Filing  
4/12/2016Christoph LengauerInsiderSell18,853$20.14$379,699.42View SEC Filing  
4/6/2016Jeffrey W AlbersCEOSell17,000$20.42$347,140.00View SEC Filing  
12/17/2015Christoph LengauerinsiderSell31,119$25.05$779,530.95View SEC Filing  
11/27/2015Fmr LlcInsiderSell287,415$21.48$6,173,674.20View SEC Filing  
11/24/2015Fmr LlcInsiderSell161,271$20.14$3,247,997.94View SEC Filing  
11/23/2015Fmr LlcInsiderSell189,572$20.15$3,819,875.80View SEC Filing  
11/19/2015Fmr LlcInsiderSell237,218$19.76$4,687,427.68View SEC Filing  
11/17/2015Fmr LlcInsiderSell27,490$20.60$566,294.00View SEC Filing  
11/3/2015Christoph LengauerinsiderSell84,998$21.05$1,789,207.90View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Blueprint Medicines Corp (NASDAQ:BPMC)
Latest Headlines for Blueprint Medicines Corp (NASDAQ:BPMC)
DateHeadline logoBlueprint Medicines to Present New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors at 2017 ASCO Annual Meeting - May 17 at 9:05 PM logoETFs with exposure to Blueprint Medicines Corp. : May 8, 2017 - May 8 at 8:55 PM logoQ2 2017 EPS Estimates for Blueprint Medicines Corp (BPMC) Boosted by Jefferies Group - May 8 at 8:21 AM logoBlueprint Medicines Corp (BPMC) Downgraded by TheStreet to "D+" - May 7 at 12:28 AM logoBlueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : May 5, 2017 - May 5 at 4:02 PM logoBlueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017 - May 5 at 4:02 PM logoEquities Analysts Offer Predictions for Blueprint Medicines Corp's Q2 2017 Earnings (BPMC) - May 5 at 9:54 AM logoWedbush Comments on Blueprint Medicines Corp's Q1 2018 Earnings (BPMC) - May 4 at 6:14 PM logoBlueprint Medicines Corp's (BPMC) Buy Rating Reaffirmed at Jefferies Group LLC - May 4 at 1:20 PM logoBlueprint Medicines Corp (BPMC) Given Daily News Sentiment Rating of 0.14 - May 3 at 11:22 PM logoBlueprint Medicines' (BPMC) CEO Jeff Albers on Q1 2017 Results - Earnings Call Transcript - May 3 at 9:06 PM logoBlueprint Medicines Corp (BPMC) Posts Earnings Results, Misses Estimates By $0.08 EPS - May 3 at 1:56 PM logoBlueprint Medicines Corp (BPMC) Given Average Rating of "Buy" by Brokerages - May 3 at 10:00 AM logoBlueprint Medicines Reports First Quarter 2017 Financial Results - May 3 at 8:23 AM logoInvestor Network: Blueprint Medicines Corp. to Host Earnings Call - May 3 at 8:23 AM logoBlueprint Medicines reports 1Q loss - May 3 at 8:23 AM logoIs There More Upside? Edition 2 - May 2 at 7:49 PM logoBlueprint Medicines Corp (BPMC) Set to Announce Quarterly Earnings on Wednesday - May 1 at 1:48 PM logo$5.96 Million in Sales Expected for Blueprint Medicines Corp (BPMC) This Quarter - April 30 at 10:36 AM logoBlueprint Medicines Corp (BPMC) Getting Somewhat Negative Press Coverage, Report Shows - April 29 at 10:04 AM logo-$0.73 EPS Expected for Blueprint Medicines Corp (BPMC) This Quarter - April 28 at 11:12 AM logoBlueprint Medicines Corp (BPMC) Sees Significant Decline in Short Interest - April 28 at 7:25 AM logoBlueprint Medicines to Report First Quarter 2017 Financial Results on Wednesday, May 3, 2017 - April 26 at 2:02 PM logoBlueprint Medicines Corp (BPMC) Earning Favorable Press Coverage, Study Shows - April 25 at 12:37 PM logoBlueprint Medicines Corp (BPMC) Receives Daily Media Impact Rating of 0.00 - April 21 at 12:37 PM logoBlueprint Medicines Corp (BPMC) Downgraded by Zacks Investment Research to "Hold" - April 18 at 8:36 PM logoBlueprint Medicines Corp (BPMC) Given Daily Coverage Optimism Rating of 0.31 - April 18 at 1:08 PM logoBlueprint Medicines Corp (BPMC) Getting Favorable Press Coverage, Analysis Shows - April 14 at 5:41 PM logo Analysts Anticipate Blueprint Medicines Corp (BPMC) Will Announce Quarterly Sales of $5.96 Million - April 8 at 8:44 AM logoBlueprint Medicines Corp (BPMC) Receives Average Rating of "Buy" from Analysts - April 7 at 8:53 PM logoBlueprint Medicines Corp to Post Q2 2017 Earnings of ($0.68) Per Share, Wedbush Forecasts (BPMC) - April 7 at 4:44 PM logoCommit To Buy Blueprint Medicines Corp At $40, Earn 18.2% Annualized Using Options - April 7 at 3:59 PM logoBlueprint Medicines Corp (BPMC) Price Target Raised to $50.00 at Wedbush - April 5 at 9:49 AM logoBlueprint Medicines Corp (BPMC) Receives Buy Rating from Canaccord Genuity - April 4 at 8:39 PM logoBlueprint Medicines to Present on BLU-285 and BLU-554 at Upcoming Scientific Conferences - March 28 at 1:04 PM logoBlueprint Medicines Corp (BPMC) Coverage Initiated by Analysts at JMP Securities - March 22 at 2:19 PM logoBlueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667 - March 21 at 6:58 AM logo4:02 pm Blueprint Medicines doses the first patient in a Phase 1 clinical trial of BLU-667 - March 21 at 6:58 AM logoInsider Selling: Blueprint Medicines Corp (BPMC) Major Shareholder Sells 30,000 Shares of Stock - March 20 at 7:28 PM logoBLUEPRINT MEDICINES CORP Financials - March 15 at 4:20 PM logoCan The Uptrend Continue for Blueprint Medicines (BPMC)? - March 14 at 9:30 AM logoBlueprint Medicines Corp (BPMC) Upgraded to “Buy” by Zacks Investment Research - March 13 at 9:22 PM logoBlueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results - March 10 at 9:54 PM logoQ4 2016 Blueprint Medicines Corp Earnings Release - Before Market Open - March 10 at 9:54 PM logoBlueprint: The Uptrend Continues In 2017 - March 10 at 4:53 PM logoEdited Transcript of BPMC earnings conference call or presentation 9-Mar-17 1:30pm GMT - March 10 at 4:53 PM logoBLUEPRINT MEDICINES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and - March 9 at 4:33 PM logoShould You Buy Blueprint Medicines (BPMC) Ahead of Earnings? - March 8 at 4:44 PM logoBlueprint Medicines Corp (BPMC) to Release Earnings on Thursday - March 8 at 7:51 AM logoNew Cambridge-based, Third Rock-backed biotech revealed in federal filing - March 7 at 9:05 PM



Blueprint Medicines Corp (BPMC) Chart for Tuesday, May, 30, 2017

This page was last updated on 5/30/2017 by Staff